WO2022150654A3 - Antigen-binding polypeptides specific for coronaviruses and uses thereof - Google Patents

Antigen-binding polypeptides specific for coronaviruses and uses thereof Download PDF

Info

Publication number
WO2022150654A3
WO2022150654A3 PCT/US2022/011714 US2022011714W WO2022150654A3 WO 2022150654 A3 WO2022150654 A3 WO 2022150654A3 US 2022011714 W US2022011714 W US 2022011714W WO 2022150654 A3 WO2022150654 A3 WO 2022150654A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigen
antibodies
coronavirus
methods
binding fragments
Prior art date
Application number
PCT/US2022/011714
Other languages
French (fr)
Other versions
WO2022150654A2 (en
Inventor
Wyatt James MCDONNELL
Bruce Alexander ADAMS
Michael John Terry STUBBINGTON
David Benjamin JAFFE
Original Assignee
10X Genomics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 10X Genomics, Inc. filed Critical 10X Genomics, Inc.
Publication of WO2022150654A2 publication Critical patent/WO2022150654A2/en
Publication of WO2022150654A3 publication Critical patent/WO2022150654A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

The present disclosure relates generally to antigen-binding polypeptides, e.g., antibodies, and antigen-binding fragments thereof, that specifically bind to the spike (S) protein of a coronavirus, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies of the disclosure are useful for inhibiting or neutralizing coronavirus activity, thus providing a means of treating or preventing coronavirus infection. Also provided are recombinant nucleic acids, recombinant cells, compositions and methods useful for identifying or producing such antibodies and antigen-binding fragments, as well as methods of using such antibodies and antigen-binding fragments for treating, preventing, or ameliorating health conditions associated with viral infections (e.g., coronavirus infections).
PCT/US2022/011714 2021-01-08 2022-01-07 Antigen-binding polypeptides specific for coronaviruses and uses thereof WO2022150654A2 (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US202163135514P 2021-01-08 2021-01-08
US63/135,514 2021-01-08
US202163164465P 2021-03-22 2021-03-22
US63/164,465 2021-03-22
US202163170337P 2021-04-02 2021-04-02
US63/170,337 2021-04-02
US202163235668P 2021-08-20 2021-08-20
US63/235,668 2021-08-20
US202163253664P 2021-10-08 2021-10-08
US63/253,664 2021-10-08

Publications (2)

Publication Number Publication Date
WO2022150654A2 WO2022150654A2 (en) 2022-07-14
WO2022150654A3 true WO2022150654A3 (en) 2022-08-25

Family

ID=82358793

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/011714 WO2022150654A2 (en) 2021-01-08 2022-01-07 Antigen-binding polypeptides specific for coronaviruses and uses thereof

Country Status (2)

Country Link
TW (1) TW202237642A (en)
WO (1) WO2022150654A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023147399A1 (en) * 2022-01-27 2023-08-03 The Rockefeller University Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
WO2023178182A1 (en) * 2022-03-16 2023-09-21 10X Genomics, Inc. Compositions and methods for detection and treatment of coronavirus infection

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086014A1 (en) * 1999-08-24 2002-07-04 Korman Alan J. Human CTLA-4 antibodies and their uses
US20080248043A1 (en) * 2006-05-19 2008-10-09 Amgen Inc. Antibodies to SARS coronavirus
US20090017017A1 (en) * 2004-07-20 2009-01-15 Symphogen A/S Anti-rhesus d recombinant polyclonal antibody and methods of manufacture
US20160024195A1 (en) * 2013-03-14 2016-01-28 Regeneron Pharmaceuticals, Inc. Human antibodies to grem1
US20170355774A1 (en) * 2016-06-10 2017-12-14 Regeneron Pharmaceuticals, Inc. Anti-gitr antibodies and uses thereof
US20180009889A1 (en) * 2013-03-14 2018-01-11 Novartis Ag Antibodies against notch 3
US20200071389A1 (en) * 2016-10-19 2020-03-05 Vanderbilt University Human orthopoxvirus antibodies and methods of use therefor

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086014A1 (en) * 1999-08-24 2002-07-04 Korman Alan J. Human CTLA-4 antibodies and their uses
US20090017017A1 (en) * 2004-07-20 2009-01-15 Symphogen A/S Anti-rhesus d recombinant polyclonal antibody and methods of manufacture
US20080248043A1 (en) * 2006-05-19 2008-10-09 Amgen Inc. Antibodies to SARS coronavirus
US20160024195A1 (en) * 2013-03-14 2016-01-28 Regeneron Pharmaceuticals, Inc. Human antibodies to grem1
US20180009889A1 (en) * 2013-03-14 2018-01-11 Novartis Ag Antibodies against notch 3
US20170355774A1 (en) * 2016-06-10 2017-12-14 Regeneron Pharmaceuticals, Inc. Anti-gitr antibodies and uses thereof
US20200071389A1 (en) * 2016-10-19 2020-03-05 Vanderbilt University Human orthopoxvirus antibodies and methods of use therefor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YUAN MENG, WU NICHOLAS C., ZHU XUEYONG, LEE CHANG-CHUN D., SO RAY T. Y., LV HUIBIN, MOK CHRIS K. P., WILSON IAN A.: "A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV", SCIENCE, vol. 368, no. 6491, 8 May 2020 (2020-05-08), US , pages 630 - 633, XP055966592, ISSN: 0036-8075, DOI: 10.1126/science.abb7269 *

Also Published As

Publication number Publication date
TW202237642A (en) 2022-10-01
WO2022150654A2 (en) 2022-07-14

Similar Documents

Publication Publication Date Title
PH12021550793A1 (en) Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments
WO2022150654A3 (en) Antigen-binding polypeptides specific for coronaviruses and uses thereof
IL187321A (en) Host cell specific binding molecules encoding monoclonal antibodies capable of neutralizing viruses, pharmaceutical compositions comprising them and uses thereof in the preparation of medicaments
BR0107613A (en) Blockade of axon growth mediated by nogo receptor
EP2532365A4 (en) Pharmaceutical composition for treatment and/or prevention of cancer
MX348154B (en) IL-1ß BINDING ANTIBODIES AND FRAGMENTS THEREOF.
AU2002305450A1 (en) Proteomimetic compounds and methods
BR0312913A (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising the same
WO2005119251A3 (en) Novel means and methods for the treatment of hearing loss and phantom hearing
WO2020169755A3 (en) Antibodies
MX2022013945A (en) Novel ankyrin repeat binding proteins and their uses.
WO2008092854A3 (en) Papillomavirus e2 polypeptide used for vaccination
EP4279128A3 (en) Novel antibody binding to tfpi and composition comprising the same
WO2005002526A3 (en) Method and compositions for treatment of viral infections
MX2022013894A (en) Neutralizing antibodies that bind the sars-cov-2 s protein.
WO2022167816A3 (en) Antibodies
MXPA04005891A (en) Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use.
WO2022170126A3 (en) Compounds specific to coronavirus s protein and uses thereof
RU2014138418A (en) PROTEINS OF SAWS AND COMPOSITIONS
WO2022011110A3 (en) Compositions and methods for the diagnosis and treatment of sars-cov-2 virus infection
NO20060675L (en) Enhanced recombinant human interferon beta-lb polypeptides
WO2005051318A3 (en) Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
WO2021216876A3 (en) Antibodies to coronavirus spike protein and methods of use thereof
WO2003022202A3 (en) Compositions and methods for treatment of cancer
ATE411812T1 (en) PEPTIDES FOR TREATING HERPES VIRUS INFECTIONS

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22737217

Country of ref document: EP

Kind code of ref document: A2